| Testicular diseases and treatments | Lifetime | 5 | DE 1 | 99.87 |
| Colorectal Cancer Treatments and Studies | Lifetime | 41 | DE 2 | 99.77 |
| Neuroblastoma Research and Treatments | Lifetime | 43 | DE 3 | 99.52 |
| Multiple Myeloma Research and Treatments | Lifetime | 57 | DE 3 | 99.55 |
| Cancer therapeutics and mechanisms | Lifetime | 93 | DE 3 | 99.34 |
| Lung Cancer Treatments and Mutations | Lifetime | 213 | DE 8 | 99.44 |
| Sarcoma Diagnosis and Treatment | Lifetime | 175 | DE 8 | 99.18 |
| Genetic factors in colorectal cancer | Lifetime | 209 | DE 7 | 99.05 |
| Cancer Treatment and Pharmacology | Lifetime | 239 | DE 11 | 99.26 |
| Neutropenia and Cancer Infections | Lifetime | 137 | DE 15 | 98.56 |
| Cancer Genomics and Diagnostics | Lifetime | 711 | DE 45 | 98.73 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 40 | DE 1 | 97.67 |
| Urologic and reproductive health conditions | Lifetime | 220 | DE 11 | 98.61 |
| Erythropoietin and Anemia Treatment | Lifetime | 130 | DE 13 | 97.65 |
| Ovarian cancer diagnosis and treatment | Lifetime | 555 | DE 17 | 97.78 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 732 | DE 27 | 97.89 |
| Chemotherapy-related skin toxicity | Lifetime | 124 | DE 4 | 95.37 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 953 | DE 43 | 96.74 |
| Sexual Differentiation and Disorders | Lifetime | 465 | DE 25 | 96.48 |
| Cancer survivorship and care | Lifetime | 707 | DE 28 | 96.10 |
| HER2/EGFR in Cancer Research | Lifetime | 965 | DE 55 | 96.21 |
| Multiple and Secondary Primary Cancers | Lifetime | 578 | DE 23 | 94.64 |
| Metastasis and carcinoma case studies | Lifetime | 940 | DE 48 | 94.53 |
| PARP inhibition in cancer therapy | Lifetime | 670 | DE 50 | 93.07 |
| Gestational Trophoblastic Disease Studies | Lifetime | 310 | DE 8 | 91.03 |
| Vascular Tumors and Angiosarcomas | Lifetime | 945 | DE 52 | 89.97 |
| Testicular diseases and treatments | 2021-2025 | 15 | DE 3 | 97.32 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 420 | DE 13 | 94.88 |
| Neuroblastoma Research and Treatments | 2021-2025 | 649 | DE 54 | 85.98 |
| Urologic and reproductive health conditions | 2021-2025 | 654 | DE 65 | 77.75 |
| Sexual Differentiation and Disorders | 2021-2025 | 571 | DE 36 | 75.44 |
| Neutropenia and Cancer Infections | 2021-2025 | 709 | DE 49 | 72.39 |
| Patient Dignity and Privacy | 2021-2025 | 800 | DE 41 | 61.12 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 875 | DE 71 | 55.90 |
| Natural Product Synthesis and Anticancer Bioactivity | 2021-2025 | 207 | DE 8 | 36.27 |
